3660-90-0

Usage

Appearance

White to pale yellow solid

Solubility

Soluble in organic solvents such as ethanol and ether

Uses

a. Intermediate in the synthesis of pharmaceuticals, dyes, and agrochemicals
b. Reagent in organic synthesis, particularly in the preparation of biologically active molecules

Bromine substituents

Useful building block for the construction of complex organic molecules

Chemical reactions

Facilitates a range of chemical reactions

Applications in materials science

Investigated for potential use in the development of new polymers with specific functional properties

Upstream product

• 85-44-9 phthalic anhydride 
• 1445-69-8 2,3-dihydrophthalazine-1,4-dione 
• 7789-69-7 phosphorus pentabromide 

Relevant academic research and scientific papers

Bis(iminopyridyl)phthalazine as a sterically hindered compartmental ligand for an M2 (M = Co, Ni, Fe, Zn) centre; Applications in ethylene oligomerisation

Abstract The new bis(iminopyridyl)phthalazine ligand, 1,4-{(2,6-i-Pr2C6H3)N=CMe)C5H3N}2C8H4N2 (L), has been prepared in good yield using a combination of palladium-mediated cross coupling and condensation strategies. Reaction of L with three equivalents of CoX2 (X = Cl, Br) in n-BuOH at elevated temperature generates, on crystallisation from bench acetonitrile, the paramagnetic tetrahalocobaltate salts [(L)Co2X(μ-X)(NCMe)m(OH2)n](CoX4) (X = Cl, m = 2, n = 1 1a; X = Br, m = 2, n = 0 1b) as acetonitrile or mixed acetonitrile/aqua adducts; a similar product is obtained from the reaction of FeCl2 with L and has been tentatively assigned as [(L)Fe2Cl(μ-Cl)(OH2)3](FeCl4) (2). By contrast, reaction of L with NiX2(DME) (X = Cl, Br; DME = 1,2-dimethoxyethane), under similar reaction conditions, affords the halide salts [(L)Ni2X2(μ-X)(OH2)2](X) (X = Cl 3a, X = Br 3b) as aqua adducts. Structural determinations on 1 and 3 reveal L to adopt a bis(tridentate) bonding mode allowing the halide-bridged metal centres to assemble in close proximity (M...M range: 3.437-3.596 ?). Unexpectedly, on reaction of L with ZnCl2, the neutral bimetallic [(L)Zn2Cl4] (4b) complex is formed in which the ZnCl2 units fill inequivalent binding sites within L (viz. the Nphth,Npy,Nim and Npy,Nim pockets). Complex 4b could also be obtained by the sequential addition of ZnCl2 to L to form firstly monometallic [(L)ZnCl2] (4a) and then on further ZnCl2 addition 4b; the fluxional behaviour of diamagnetic 4a and 4b is also reported. On activation with excess methylaluminoxane (MAO), 1-3 display modest activities for ethylene oligomerisation forming low molecular weight waxes with methyl-branched products predominating for the nickel systems (3). On the other hand, the iron catalyst (2) gives exclusively α-olefins while the cobalt systems (1) are much less selective affording equal mixtures of α-olefins and internal olefins along with lower levels of vinylidenes and tri-substituted alkenes. Single crystal X-ray structures are reported for L, 1a, 1b, 3a, 3b and 4.

The synthesis and anti‐tumour properties of novel 4-substituted phthalazinones as Aurora B kinase inhibitors

A series of novel 4-substituted phthalazinones as Aurora B kinase inhibitors was synthesized and evaluated the anti-proliferative activities against A549, HCT116, MCF-7 and HepG2 cells. 1-(4-(2-((4-Oxo-3,4-dihydrophthalazin-1-yl)amino)ethyl) phenyl)-3-(3-(trifluoromethyl)phenyl)urea (17b) exhibited the most potent anti-proliferative activity against HCT116 cells with IC50 value of 4.35 ± 1.21 μM, as well as the moderate Aurora B inhibitory activity with the IC50 value of 142 nM. Furthermore, 17b inhibited the phosphorylation of Aurora B on Thr232, leading to cell cycle arrest in the G2/M phase by down-regulating the expression of CyclinB1 and Cdc2 proteins, and apoptosis by up-regulating the expression of BAD and Bax proteins in HCT116 cells. In addition, a docking study revealed that 17b could form key hydrogen bonds with Ala173, Glu171 and Glu177 in Aurora B. All the results reveal that 17b is worthy of further development as an Aurora B kinase inhibitor.

Synthesis and biological evaluation of 2,4-disubstituted phthalazinones as Aurora kinase inhibitors

A series of 2,4-disubstituted phthalazinones were synthesized and their biological activities, including antiproliferation, inhibition against Aurora kinases and cell cycle effects were evaluated. Among them, N-cyclohexyl-4-((4-(1-methyl-1H-pyrazol-4-yl)-1-oxophthalazin-2(1H)-yl) methyl) benzamide (12c) exhibited the most potent antiproliferation against five carcinoma cell lines (HeLa, A549, HepG2, LoVo and HCT116 cells) with IC50 values in range of 2.2–4.6 μM, while the IC50 value of reference compound VX-680 was 8.5–15.3 μM. Moreover, Aurora kinase assays exhibited that compound 12c was potent inhibitor of AurA and AurB kinase with the IC50 values were 118 ± 8.1 and 80 ± 4.2 nM, respectively. Molecular docking studies indicated that compound 12c forms better interaction with both AurA and AurB. Furthermore, compound 12c induced G2/M cell cycle arrest in HeLa cells by regulating protein levels of cyclinB1 and cdc2. These results suggested that 12c is a promising pan-Aurora kinase inhibitor for the potential treatment of cancer.

ORGANIC COMPOUND AND LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DIODE DISPLAY DEVICE USING THE SAME

The present invention relates to an organic compound which ensures excellent hole injection properties and charge generation properties, since an electron withdrawing group (an electron acceptor) is substituted at a core of a heteroaromatic derivative such as conjugated pyridazine. The present invention further relates to a light-emitting diode to which the organic compound is applied to at least one organic layer, and a display device.COPYRIGHT KIPO 2017

Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship

In this study, starting from a lead compound discovered by virtual screening, a series of novel heterocyclic substituted benzenesulfonamides were designed and synthesized as new carbonic anhydrase IX (CA IX) inhibitors. Some compounds exhibited potent inh

Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase

The inhibition of Aurora kinases in order to arrest mitosis and subsequently inhibit tumor growth via apoptosis of proliferating cells has generated significant discussion within the literature. We report a novel class of Aurora kinase inhibitors based upon a phthalazinone pyrazole scaffold. The development of the phthalazinone template resulted in a potent Aurora-A selective series of compounds (typically >1000-fold selectivity over Aurora-B) that display good pharmacological profiles with significantly improved oral bioavailability compared to the well studied Aurora inhibitor VX-680.

DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS

The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.

NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS

Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.